A new research report published by Transparency Market Research states that the global
osteoporosis drugs market will grow due to increasing prevalence of osteoporosis. The report, titled
“Osteoporosis Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth,
Trends & Forecast 2014 - 2020”, is compiled with accurate information regarding the market. The
industry experts have used SWOT analysis and Porter’s five forces analysis to analyze the key
trends and dynamics likely to impact this market.
The global osteoporosis market is segmented on the basis of drug class and geography. On the basis
of drug class, the global osteoporosis market is segmented into bisphosphonates, parathyroid
hormone therapy (PTH) drugs, selective estrogen receptor modulators (SERMs), RANK ligand
inhibitors, calcitonin, and other such as others Vitamin D and calcium. This segment also includes
drugs that are in the pipeline. Geographically, this market is segmented into Europe, North America,
Asia Pacific, and Rest of the World.
Read Report Overview @ https://www.transparencymarketresearch.com/osteoporosis-drugmarket.html
Out of the drug class segments, bisphosphonates were the fastest growing segment and held 48.2%
of the overall osteoporosis drugs market in 2013. However, analysts predict that pipeline drugs will
showcase accelerated growth at a CAGR of 125.20% from 2014 to 2020.The International
Osteoporosis Foundation (IOF) stated that at least 9 mn fractures and bone cracks occur every year.
In addition to this, about 200 mn women across the world are expected to be victims of osteoporosis
with each passing year. With these alarming figures, growth of the global osteoporosis drug is only
expected to accelerate. In addition, introduction of new drug classes that hold the promise of
overcoming the threat of chronic and generics side effects of the established drugs is yet another
factor making a positive influence on the growth of the global osteoporosis drugs market.
In terms of geography, North America holds a major share in the global osteoporosis drugs market.
This can be credited to the presence of a huge pool of patients suffering from osteoporosis, growing
awareness about the disease, technological advancements and adoption of the same, and presence of
state-of-the-art medical infrastructure. However, the research report predicts that Asia Pacific will
be the next region to create a huge wave of demand in the osteoporosis drugs market from 2014 to
2020.
Some of the important players in the global osteoporosis drugs market are Novartis International
AG, Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc., and Amgen, Inc., Teva Pharmaceutical
Industries Ltd., F. Hoffmann La Roche Ltd., Actavis plc, and Novo Nordisk A/S. The report opens a
discussion about the competitive landscape of the global osteoporosis drugs market and states
details pertaining to company overview, financial overview, research and development activities,
business and marketing strategies, and lists the existing products and those in the pipeline.
Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?
flag=S&rep_id=133